Literature DB >> 33345802

Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019: analysis of the Mexican National Surveillance Program.

Raigam Jafet Martinez-Portilla1, Emily R Smith2, Siran He2, Johnatan Torres-Torres3, Salvador Espino-Y-Sosa3, Juan Mario Solis-Paredes4, Liona C Poon5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33345802      PMCID: PMC7837025          DOI: 10.1016/j.ajog.2020.12.1197

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


× No keyword cloud information.

Objective

There is conflicting information regarding whether pregnant women are at increased risk of severe complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to understand whether pregnant women are at increased risk of death or severe illness owing to coronavirus disease 2019 (COVID-19) compared with nonpregnant women and whether that risk varies by age.

Study Design

Data were extracted from the epidemiologic surveillance system of viral respiratory diseases of Mexico, which included 475 monitoring hospitals that are components of the Mexican Public Health Network, including the National Mexican Institute of Social Security, Institute of Security and Social Services for State Workers, Secretary of National Defense, Secretary of the Navy of the Mexican Republic, and the National Health Department. These monitoring hospitals were given the approval to perform reverse transcription polymerase chain reaction analysis for SARS-CoV-2 in Mexico and are, therefore, the reference centers for all patients with suspected COVID-19. We included 7028 pregnant and 255,721 nonpregnant women aged 15 to 45 years diagnosed as having COVID-19 between February 1, 2020, and October 27, 2020.

Results

We found that the risk of death and pneumonia increased with age for both pregnant and nonpregnant women (Figure , A and C). The adjusted case fatality rate for pregnant women was 1.3% overall but rose to 2.1% and 5.9% for those aged 35 to 39 years and 40 to 44 years, respectively. Pregnant women with COVID-19 consistently had a higher risk of death and pneumonia than nonpregnant women of similar age with COVID-19 (adjusted relative risk [RR] of death, 1.68; 95% confidence interval [CI], 1.36–2.08; adjusted RR of pneumonia, 1.97; 95% CI, 1.82–2.13) (Figure; Table ). Although the risk was highest among older pregnant women, the highest RRs appeared among both younger and older pregnant women (Figure, B and D).
Figure

Risk of death and pneumonia among pregnant and nonpregnant women

A, Absolute risk of death and 95% confidence intervals by patient age, stratified by pregnant and nonpregnant women (nonlinear relationship between the risk of death and age modeled using restricted cubic splines). B, Relative risk of death of pregnant and nonpregnant women with COVID-19 by age categories. C, Absolute risk of pneumonia and 95% confidence intervals by patient age, stratified by pregnant and nonpregnant women (nonlinear relationship between the risk of death and age modeled using restricted cubic splines). D, Relative risk of pneumonia of pregnant and nonpregnant women with COVID-19 by age categories.

COVID-19, coronavirus disease 2019.

Martinez-Portilla. Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019. Am J Obstet Gynecol 2021.

Table

Relative risk of death and pneumonia between pregnant and nonpregnant women with coronavirus disease 2019 (age, 15–44 years)

VariablesDeathbPregnancy
Nonpregnant
RR (95% CI)P valueAdjusted RR (95% CI)aP value
EventsTotalRisk per 100,000EventsTotalRisk per 100,000
Overall93702813203221255,72112601.61 (1.28–2.02)<.0011.68 (1.36–2.08)<.001
Age 15–<20 y24514445810,8445300.83 (0.20–3.38).790.83 (0.20–3.41).80
Age 20–<25 y161505106012829,2574402.43 (1.45–4.08).00082.24 (1.29–3.90).004
Age 25–<30 y18210286025549,5925101.67 (1.03–2.68).041.66 (1.02–2.71).04
Age 30–<35 y231768130047453,3778901.47 (0.97–2.22).071.49 (0.97–2.27).07
Age 35–<40 y20963208070952,24613601.53 (0.99–2.38).061.50 (0.95–2.36).08
Age 40–<45 y142395860159760,40526402.22 (1.32–3.69).0022.30 (1.37–3.85).002

CI, confidence interval; RR, relative risk.

Martinez-Portilla. Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019. Am J Obstet Gynecol 2021.

Modified Poisson model adjusted for obesity, hypertension, diabetes, and smoking

P value for interaction (maximum likelihood test comparing full and reduce models, 5 degrees of freedom) between pregnancy and age (5-year age bin categories) is equal to .46

P value for interaction (maximum likelihood test comparing full and reduce models, 5 degrees of freedom) between pregnancy and age (5-year age bin categories) is equal to .002.

Risk of death and pneumonia among pregnant and nonpregnant women A, Absolute risk of death and 95% confidence intervals by patient age, stratified by pregnant and nonpregnant women (nonlinear relationship between the risk of death and age modeled using restricted cubic splines). B, Relative risk of death of pregnant and nonpregnant women with COVID-19 by age categories. C, Absolute risk of pneumonia and 95% confidence intervals by patient age, stratified by pregnant and nonpregnant women (nonlinear relationship between the risk of death and age modeled using restricted cubic splines). D, Relative risk of pneumonia of pregnant and nonpregnant women with COVID-19 by age categories. COVID-19, coronavirus disease 2019. Martinez-Portilla. Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019. Am J Obstet Gynecol 2021. Relative risk of death and pneumonia between pregnant and nonpregnant women with coronavirus disease 2019 (age, 15–44 years) CI, confidence interval; RR, relative risk. Martinez-Portilla. Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019. Am J Obstet Gynecol 2021. Modified Poisson model adjusted for obesity, hypertension, diabetes, and smoking P value for interaction (maximum likelihood test comparing full and reduce models, 5 degrees of freedom) between pregnancy and age (5-year age bin categories) is equal to .46 P value for interaction (maximum likelihood test comparing full and reduce models, 5 degrees of freedom) between pregnancy and age (5-year age bin categories) is equal to .002.

Conclusion

Earlier reports suggested that mortality may not be higher in pregnant women with COVID-19. However, a recent US study found a 1.7-fold increased risk of death in pregnant women (n=34) with COVID-19 compared with nonpregnant women (n=447). We confirm that pregnancy puts the women at increased risk of COVID-19–related death and pneumonia, as we have suggested in our previous article using a propensity score matching analysis. What was striking about our results was that although the risk was highest among older pregnant women, the RR was high among younger pregnant women aged between 20 and 30 years. This likely reflected both the excess risk conferred by pregnancy and the low baseline risk of death and severe disease among younger nonpregnant women. The finding was concerning. Younger populations have been reassured that they are at lower risk of experiencing COVID-19–related complications, and pregnant women may falsely believe that their young age protects them against severe diseases. Such inadequate health advice may render this vulnerable group to seek medical care too late, and care may not be prioritized appropriately if they are perceived to be at lower risk. Therefore, pregnancy puts the woman at an increased risk of COVID-19–related death and pneumonia. All pregnant women, irrespective of age, should be informed about the health risks associated with COVID-19 and should seek medical help at the earliest opportunity.
  5 in total

1.  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Pregnancy in Sub-Saharan Africa: A 6-Country Retrospective Cohort Analysis.

Authors:  Jean B Nachega; Nadia A Sam-Agudu; Rhoderick N Machekano; Philip J Rosenthal; Sonja Schell; Liesl de Waard; Adrie Bekker; Onesmus W Gachuno; John Kinuthia; Nancy Mwongeli; Samantha Budhram; Valerie Vannevel; Priya Somapillay; Hans W Prozesky; Jantjie Taljaard; Arifa Parker; Elizabeth Agyare; Akwasi Baafuor Opoku; Aminatu Umar Makarfi; Asara M Abdullahi; Chibueze Adirieje; Daniel Katuashi Ishoso; Michel Tshiasuma Pipo; Marc B Tshilanda; Christian Bongo-Pasi Nswe; John Ditekemena; Lovemore Nyasha Sigwadhi; Peter S Nyasulu; Michel P Hermans; Musa Sekikubo; Philippa Musoke; Christopher Nsereko; Evans K Agbeno; Michael Yaw Yeboah; Lawal W Umar; Mukanire Ntakwinja; Denis M Mukwege; Etienne Kajibwami Birindwa; Serge Zigabe Mushamuka; Emily R Smith; Edward J Mills; John Otokoye Otshudiema; Placide Mbala-Kingebeni; Jean-Jacques Muyembe Tamfum; Alimuddin Zumla; Aster Tsegaye; Alfred Mteta; Nelson K Sewankambo; Fatima Suleman; Prisca Adejumo; Jean R Anderson; Emilia V Noormahomed; Richard J Deckelbaum; Jeffrey S A Stringer; Abdon Mukalay; Taha E Taha; Mary Glenn Fowler; Judith N Wasserheit; Refiloe Masekela; John W Mellors; Mark J Siedner; Landon Myer; Andre-Pascal Kengne; Marcel Yotebieng; Lynne M Mofenson; Eduard Langenegger
Journal:  Clin Infect Dis       Date:  2022-06-08       Impact factor: 20.999

2.  Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing.

Authors:  Ricardo Savirón-Cornudella; Ana Villalba; Luis M Esteban; Mauricio Tajada; Belén Rodríguez-Solanilla; Mercedes Andeyro-Garcia; Javier Zapardiel; Segundo Rite; Berta Castán-Larraz; Faustino R Pérez-López
Journal:  Life Sci       Date:  2021-02-09       Impact factor: 6.780

3.  Scientific effort in combating COVID-19 in obstetrics and gynecology.

Authors:  R J Martinez-Portilla; M M Gil; L C Poon
Journal:  Ultrasound Obstet Gynecol       Date:  2021-02       Impact factor: 7.299

4.  Twin-to-twin transfusion syndrome and coronavirus disease 2019: impact on diagnosis, referral, eligibility for fetoscopic laser therapy, and outcomes.

Authors:  Hugo López-Briones; Rosa Villalobos-Gómez; Eréndira Chávez-González; Miguel Martínez-Rodríguez; Antonio Helue-Mena; Alma Gámez-Varela; Rogelio Cruz-Martinez
Journal:  AJOG Glob Rep       Date:  2022-01-13

5.  Increased levels of soluble fms-like tyrosine kinase-1 are associated with adverse outcome in pregnant women with COVID-19.

Authors:  J Torres-Torres; S Espino-Y-Sosa; L C Poon; J M Solis-Paredes; G Estrada-Gutierrez; A Espejel-Nuñez; A Juarez-Reyes; A Etchegaray-Solana; Y Alfonso-Guillen; L Aguilar-Andrade; J A Hernández-Pacheco; J R Villafan-Bernal; R J Martinez-Portilla
Journal:  Ultrasound Obstet Gynecol       Date:  2021-12-29       Impact factor: 8.678

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.